Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes.

ABSTRACT:

Background

Recent studies suggest that immunotherapy using T regulatory cells (Tregs) prolongs remission in type 1 diabetes (T1DM). Here, we report factors that possibly affect the efficacy of this treatment.

Methods

The metabolic and immune background of 12 children with recently diagnosed T1DM, as well as that of untreated subjects, during a 2-year follow-up is presented. Patients were treated with up to 30 × 10⁶/kg b.w. of autologous expanded CD3⁺CD4⁺CD25^highCD127^- Tregs.

Results

The disease progressed and all patients were insulin-dependent 2 years after inclusion. The β-cell function measured by c-peptide levels and the use of insulin were the best preserved in patients treated with two doses of Tregs (3/6 in

SUBMITTER: Marek-Trzonkowska N 

PROVIDER: S-EPMC5131539 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature